Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO , April 28, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company's Chief Executive Officer, Mark Gergen, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 2:40pm PT in Las Vegas. A live webcast of the presentation will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and financial results for the fourth quarter and full year ended December 31, 2021. "We continued to demonstrate strong progress on our key priorities in the fourth quarter even as the pandemic impacted all parts of our industry.

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT. Poseida Therapeutics hosts R&D Day focused on novel pipeline and technology innovations.

Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022. "Brent brings deep pharmaceutical expertise and a strong track record of leadership in gene therapy and rare genetic diseases to Poseida, and I am excited to welcome him to our team," said Mark Gergen, Chief Executive Officer of Poseida.

Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy

SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data are being presented today at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in a poster presentation entitled, "Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 23, 2022. Poseida to host second annual Virtual R&D Day on February 23, 2022.

Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Eric Ostertag as Executive Chairman and the transition of current President and Chief Business Officer, Mark Gergen, to the role of Chief Executive Officer effective as of February 1, 2022. The Company also provided a summary business update and 2022 preview.

Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen

SAN DIEGO, Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-MUC1C-ALLO1, the Company's allogeneic CAR-T product candidate targeting multiple solid tumor indications.  Poseida announces FDA clearance of IND for P-MUC1C-ALLO1, a fully #allogeneic CAR-T targeting multiple solid tumors.

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

Poseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Poseida Therapeutics, Inc. (PSTX) Moves to Buy: Rationale Behind the Upgrade

SAN DIEGO , Dec. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 2021 American Society of Hematology (ASH) Annual Meeting. The results show that P-BCMA-101, a non-viral transposon-based autologous CAR-T, was well tolerated and demonstrated strong anti-tumor activity in advanced, late line R/R MM patients.

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 276.7% in Poseida Therapeutics, Inc. (PSTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Poseida Therapeutics, Inc. (PSTX) Could Surge 277%: Read This Before Placing a Bet

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the third quarter ended September 30, 2021. "The last quarter saw continued progress as Poseida reached multiple key strategic milestones including FDA clearance of our first fully allogeneic CAR-T IND for P-BCMA-ALLO1, the presentation of strong CAR-T data in a solid tumor indication with our P-PSMA-101 program and, shortly after the quarter, the announcement of a strategic collaboration with Takeda focused on non-viral in vivo gene therapy programs utilizing our platform technologies," said Eric Ostertag, M.D.

Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the upcoming presentation of preclinical data highlighting P-BCMA-ALLO1 for the treatment of relapsed/refractory multiple myeloma and P-MUC1C-ALLO1 for the treatment of multiple solid tumor indications at the Society for Immunotherapy of Cancer 2021 Annual Meeting (SITC), being held in Washington, D.C., and virtually November 10-14, 2021.

Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to a 281% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences: Stifel 2021 Virtual Healthcare Conference Date: Tuesday, November 16, 2021 Time: 2:40pm ET Piper Sandler 33rd Annual Virtual Healthcare Conference Date: Monday, November 22, 2021 Time: Pre-record available at 10:00am ET Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com.  An archived replay of each webcast will be available for approximately 30 days following each presentation.

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

Poseida has built a non-viral genome engineering platform to develop safer cell therapies in oncology. This platform could enable outpatient use and expand the number of patients who can receive a cell therapy as well as bringing in substantial partnerships.

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

SAN DIEGO, Oct. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team. Effective immediately, Johanna Mylet, C.P.A.

Poseida Therapeutics Announces Leadership Appointments

Shares of Poseida Therapeutics Inc. PSTX, +1.22% were up 9.6% in premarket trading on Tuesday after the company said it signed a research and licensing agreement with Takeda Pharmaceutical Co. Ltd. 4502, -0.12% to study and commercialize up to eight gene therapies.

A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has entered into a research collaboration and exclusive license agreement with Takeda Pharmaceutical Company Limited ("Takeda") to utilize Poseida's piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on developing non-viral in vivo gene therapy programs, including Poseida's Hemophilia A program.

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

SAN DIEGO, Oct. 1, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C., and virtually November 10-14, 2021.

Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting

The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy. The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer (mCRPC).

Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors

SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data will be presented at the 6th Annual CAR-TCR Summit virtual meeting at 10:00am ET today in a presentation entitled, "P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer.

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

The FDA has cleared Poseida Therapeutics Inc (NASDAQ: PSTX) Investigational New Drug (IND) application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsed/refractory multiple myeloma. The Phase 1 study will assess safety, tolerability, and response.

Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-BCMA-ALLO1, the Company's first fully allogeneic CAR-T product candidate for patients with relapsed/refractory multiple myeloma. Poseida announces FDA clearance of IND for its first fully #allogeneic CAR-T therapy for patients with multiple myeloma.

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

News for Poseida Therapeutics Stock (PSTX)